ExpreS2ion announces interim results for the first nine months of 2020
Hørsholm, Denmark, November 19, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its interim financial results for the first nine months of 2020 and the third quarter of 2020. The Interim Report (Q3) is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “One reason – perhaps the main reason – I am so pleased with our recent capital raise is that we can now finally get to work on the HER2 VLP breast cancer vaccine AV001. There is a good chance that with the investments we make